Recombinant Human TFF2 Protein, Myc/DDK-tagged, C13 and N15-labeled

• Cat.No.: TFF2-5458H
• Product Overview: TFF2 MS Standard C13 and N15-labeled recombinant protein (NP_005414) with a C-terminal MYC/DDK tag, was expressed in HEK293 cells.

Specification

• Description: Members of the trefoil family are characterized by having at least one copy of the trefoil motif, a 40-amino acid domain that contains three conserved disulfides. They are stable secretory proteins expressed in gastrointestinal mucosa. Their functions are not defined, but they may protect the mucosa from insults, stabilize the mucus layer and affect healing of the epithelium. The encoded protein inhibits gastric acid secretion. This gene and two other related trefoil family member genes are found in a cluster on chromosome 21.
• Source: HEK293
• Species: Human
• Tag: Myc/DDK
• Molecular Mass: 14.3 kDa
• AA Sequence: MGRRDAQLLAALLVLGLCALAGSEK PSPCQCSRLSPHNRTNCGFPGITSD QCFDNGCCFDSSVTGVPWCFHPLPK QESDQCVMEVSDRRNCGYPGISPEE CASRKCCFSNFIFEVPWCFFPKSVE DCHYTRTRPLEQKLISEEDLAANDI LDYKDDDDKV
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining
• Stability: Stable for 3 months from receipt of products under proper storage and handling conditions.
• Storage: Store at -80 centigrade. Avoid repeated freeze-thaw cycles.
• Concentration: 50 μg/mL as determined by BCA
• Storage Buffer: 100 mM glycine, 25 mM Tris-HCl, pH 7.3.

Gene Information

• Gene Name: TFF2 trefoil factor 2 [ Homo sapiens (human) ]
• Official Symbol: TFF2
• Synonyms: TFF2; trefoil factor 2; SML1, spasmolytic protein 1; spasmolysin; spasmolytic protein 1; spasmolytic polypeptide; SP; SML1
• Gene ID: 7032
• mRNA Refseq: NM_005423
• Protein Refseq: NP_005414
• MIM: 182590
• UniProt ID: Q03403

Reviews

03/14/2020

The manufacturer's technical support can also aid researchers in the data analysis phase.

12/17/2018

the manufacturer's technical support is instrumental in assisting researchers throughout their trials.

04/15/2016

They can provide valuable guidance in experimental design, optimization, and troubleshooting, helping researchers overcome challenges and maximize the efficiency of their trials.

Q&As

How does TFF2 protein contribute to the protection of the gastric mucosa?

TFF2 promotes the formation of a protective mucous layer on the stomach lining, preventing damage from stomach acid and other harmful factors.

Can TFF2 protein be administered orally for clinical applications?

Researchers are exploring various methods of delivering TFF2 protein, including oral administration, to treat gastrointestinal conditions.

In what ways is TFF2 protein being studied for potential therapeutic applications in IBD?

TFF2 is being investigated for its potential to reduce inflammation and promote mucosal healing in IBD patients.

Are there ongoing clinical trials or research investigating the therapeutic potential of TFF2 protein?

Yes, there are ongoing studies exploring the use of TFF2 protein in the treatment of various gastrointestinal disorders.

How does TFF2 protein compare to other treatments for gastric ulcers or IBD?

TFF2 protein-based therapies may offer an alternative or complementary approach to traditional treatments for these conditions.